BillionToOne

BillionToOne is a next-generation molecular diagnostics company on a mission to make powerful, accurate diagnostic tests accessible to everyone. Founded by experts with backgrounds from top tech companies, BillionToOne has developed revolutionary QCT molecular counting technology that enhances disease detection resolution by over a thousandfold using cell-free DNA. This breakthrough has already transformed the lives of over half a million patients worldwide. The company offers a range of innovative products including Unity Complete™, the only non-invasive prenatal screen capable of assessing fetal risk for common and severe recessive gene disorders, chromosomal abnormalities, fetal sex, and fetal antigens from a single maternal blood sample. In oncology, their Northstar® liquid biopsy test uniquely combines treatment selection with real-time monitoring for unprecedented precision in cancer care. With nearly $400 million in funding from prestigious investors like Hummingbird, Adams Street Partners, and Premji Invest, BillionToOne has grown from $0 to $125 million in Annual Recurring Revenue in just four years. The company is ranked among Y Combinator’s top 5% and has received recognition as a Best Startup Employer. BillionToOne fosters an open, transparent culture with weekly Town Hall meetings and offers exceptional benefits including 100% employer-paid healthcare, generous parental leave, and state-of-the-art facilities. They are committed to redefining healthcare through molecular diagnostics while maintaining a collaborative, innovative environment where employees can directly impact patient outcomes and drive meaningful change in medicine.